News | PET Imaging | April 19, 2021

Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

New PET imaging agent for rapid monitoring tumor response to therapy

olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Professor Fabian Kiessling, M.D., Director of the Institute for Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany commented, “In addition to monitoring tumor response to therapy, a tracer that sees necrosis should track organ fibrosis in chronic kidney disease and liver fibrosis. These diseases are common, but their progression and responses to therapy are still hard to track reliably. 18F-FGA could be extremely valuable to fill this unmet medical need.”

Professor Vibhudutta Awasthi, Ph.D., Associate Dean of Research, inventor and co-inventor Hailey Houson, M.D., at the University of Oklahoma said, “An 18F-FGA imaging agent for necrosis can revolutionize a diagnostic workup of many human diseases where tissue necrosis occurs as part of the pathology. This tracer enables use of high resolution, high sensitivity PET, to detect myocardial infarction and brain stroke. We are delighted to hear about MTTI’s effort to commercialize this technology.”

“The search for agents that could image necroses, without accumulating in living tissue, has been going on for decades. This innovative 18F PET tracer is specific for dead cells. It is also ideal for monitoring rapid tumor response to radiation and drug treatment. We’re excited for this discovery and look forward to advancing this molecule to clinic,” said Chris Pak, President and CEO of MTTI.

Molecular Targeting Technologies, Inc. is a privately held, clinical stage biotech company, developing targeted radiotherapeutics for rare cancers. Our lead platform technology is owned under an exclusive worldwide license to commercialize Evans blue (EB) platform patents from NIH. This transformative technology has applications in several cancers overexpressing somatostatin receptor type 2 (SSTR2), like Hürthle Cell Thyroid Carcinoma. The company is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical therapy assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to orchestrate multiple clinical trials in 2021.

For more information: www.mtarget.com.

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
Ramon Alfredo Siochi, Ph.D. — the director of medical physics at WVU — led a task group to help ensure the accuracy of data that dictates a cancer patient's radiation therapy.

Ramon Alfredo Siochi, director of medical physics at West Virginia University. Image courtesy of WVU Photo/Aira Burkhart

News | Radiation Oncology | July 15, 2021
July 15, 2021 — Just as helicopter traffic reporters use their "bird's eye view" to route drivers around roadblocks s
 The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.

Getty Images

News | Radiation Oncology | July 12, 2021
July 12, 2021 — The numbers of...